A randomised, double-blind, placebo-controlled, parallel-group efficacy and safety comparison of one-year treatment of two doses (5mg and 10mg) of tiotropium inhalation solution delivered by the Respimat device in patients with chronic obstructive pulmonary disease (COPD).

Trial Profile

A randomised, double-blind, placebo-controlled, parallel-group efficacy and safety comparison of one-year treatment of two doses (5mg and 10mg) of tiotropium inhalation solution delivered by the Respimat device in patients with chronic obstructive pulmonary disease (COPD).

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2010 Additional trial location identified as reported by ClinicalTrials.gov.
    • 16 Jul 2010 Additional trial locations identified as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Actual patient number (1007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top